Anti-cytokine biologics (infliximab, adalimumab, ustekinumab) are known to reduce the expression levels of ACE2 [18], which may contribute to the lack of association between the risk of SARS-CoV-2 infection and in general treatment with biologicals [3] in patients with IBD. The gene discussed is ACE2; the disease is inflammatory bowel disease.